- Home
- ALT vs KAZR Comparison
ALT vs KAZR Comparison
Compare ALT & KAZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.91
N/A
Current Price
$1.93
Company Overview
Basic Information| Metric | ALT | KAZR |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Engineering & Construction |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.5M | 398.1M |
| IPO Year | 2005 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ALT | KAZR |
|---|---|---|
| Price | $2.91 | $1.93 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $17.67 | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 144.5K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 105.00 | N/A |
| 52 Week Low | $2.56 | $1.60 |
| 52 Week High | $6.44 | $3.20 |
Technical Indicators
Market Signals| Indicator | ALT | KAZR |
|---|---|---|
| Relative Strength Index (RSI) | 50.38 | 27.10 |
| Support Level | $2.87 | N/A |
| Resistance Level | $3.09 | $3.07 |
| Average True Range (ATR) | 0.17 | 0.31 |
| MACD | -0.00 | -0.09 |
| Stochastic Oscillator | 30.36 | 8.21 |
Price Performance
Historical Comparison ALT
KAZR
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.